Skandinaviska Enskilda Banken AB publ Buys New Shares in Exelixis, Inc. (NASDAQ:EXEL)

Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,600 shares of the biotechnology company's stock, valued at approximately $425,000.

Other large investors have also bought and sold shares of the company. FMR LLC raised its holdings in shares of Exelixis by 6.1% in the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock valued at $63,891,000 after purchasing an additional 140,568 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in Exelixis by 20.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock valued at $71,828,000 after buying an additional 366,141 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Exelixis by 6.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company's stock worth $44,182,000 after buying an additional 98,000 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after buying an additional 704,786 shares during the last quarter. Finally, Systematic Financial Management LP increased its position in shares of Exelixis by 7.1% during the third quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company's stock valued at $30,320,000 after acquiring an additional 77,599 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

EXEL has been the subject of a number of recent analyst reports. StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Wells Fargo & Company lowered shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price target for the company. in a research report on Monday, February 24th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Exelixis in a research report on Thursday, February 13th. Royal Bank of Canada increased their target price on shares of Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Price Performance

NASDAQ:EXEL traded down $0.22 during trading hours on Friday, hitting $36.96. The stock had a trading volume of 7,318,907 shares, compared to its average volume of 2,092,892. The company has a 50 day simple moving average of $35.59 and a two-hundred day simple moving average of $32.74. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 over the last three months. 2.85% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.